Royalty Pharma (RPRX) Loans and Notes Receivables (2019 - 2025)
Royalty Pharma's Loans and Notes Receivables history spans 7 years, with the latest figure at $854.4 million for Q4 2025.
- For Q4 2025, Loans and Notes Receivables rose 9.01% year-over-year to $854.4 million; the TTM value through Dec 2025 reached $854.4 million, up 9.01%, while the annual FY2025 figure was $854.4 million, 9.01% up from the prior year.
- Loans and Notes Receivables for Q4 2025 was $854.4 million at Royalty Pharma, down from $860.1 million in the prior quarter.
- Across five years, Loans and Notes Receivables topped out at $860.1 million in Q3 2025 and bottomed at $522.4 million in Q1 2021.
- The 5-year median for Loans and Notes Receivables is $703.9 million (2022), against an average of $697.3 million.
- The largest annual shift saw Loans and Notes Receivables rose 16.58% in 2022 before it increased 2.77% in 2024.
- A 5-year view of Loans and Notes Receivables shows it stood at $614.4 million in 2021, then increased by 12.53% to $691.3 million in 2022, then grew by 6.82% to $738.4 million in 2023, then increased by 6.14% to $783.8 million in 2024, then grew by 9.01% to $854.4 million in 2025.
- Per Business Quant, the three most recent readings for RPRX's Loans and Notes Receivables are $854.4 million (Q4 2025), $860.1 million (Q3 2025), and $842.9 million (Q2 2025).